Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;97(7):E232-E235.
doi: 10.1002/ajh.26546. Epub 2022 Mar 30.

Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Talha Badar  1 , Ehab Atallah  2 , Rory M Shallis  3 , Aaron D Goldberg  4 , Anand Patel  5 , Yasmin Abaza  6 , Jan P Bewersdorf  3 , Antoine N Saliba  7 , Guilherme Sacchi De Camargo Correia  8 , Guru Murthy  2 , Adam Duvall  5 , Madelyn Burkart  6 , Maximilian Stahl  9 , Yuanhang Liu  10 , Shira Dinner  6 , Neil Palmisiano  11 , Mark R Litzow  7 , James M Foran  1
Affiliations
Free article

Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Talha Badar et al. Am J Hematol. 2022 Jul.
Free article
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2009;23(1):203-206.
    1. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684-2692.
    1. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17.
    1. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.
    1. Goldberg AD, Talati C, Desai P, et al. TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia. Blood. 2018;132(Supplement 1):1433.

Publication types

MeSH terms

Substances